Poster Presentations – Sunday, October 19, 3:30 pm - 7:00 pmP439. Clinical Characteristics and Natural History of Crohn’s DiseasePatients With Endoscopic Skipping of Distal Terminal Ileum on IleoscopyParakkal Deepak, MBBS, Joel Fletcher, MD, Jeff Fidler, MD, SunilSamuel, MBBS, PhD, Edward Loftus, MD, FACG, John Barlow, MD,Stephanie Hansel, MD, Brenda Becker, BSc, Ishrat Mansuri, MBBS,David Bruining, MD, Division of Gastroenterology and Hepatology,Mayo Clinic, Rochester, MN, Department of Radiology, Mayo Clinic,Rochester, MN, Division of Gastroenterology and Hepatology,Nottingham University Hospitals NHS Trust, Nottingham, UnitedKingdom, Division of Pediatric Gastroenterology and Hepatology, MayoClinic, Rochester, MNP440. CD4 Count Does Not Impact Disease Severity in HIV PositivePatients With Ulcerative ColitisMeira Abramowitz, MD, Rajesh Ramachandran, MD, Charles Koczka,MD, Garrett Lawlor, MD, SUNY Downstate Medical Center, Brooklyn,NY, VA Harbor Health System, Brooklyn, NYP441. Hispanic Ethnicity Is Associated With Milder Disease Severity inCrohn’s Disease but Not Ulcerative ColitisChristie Choi, MD, Amit Singal, MD, MS, Kunjali Padhya, MD, AvegailFlores, MD, Prabhakar Swaroop, MD, Ezra Burstein, MD, TasneemAhmed, DO, Digestive Diseases, University of Texas SouthwesternMedical Center, Dallas, TXP442. Vedolizumab Induces Clinical Response and Remission Across aRange of Baseline Fecal Calprotectin Levels in Patients With UlcerativeColitis: Results From GEMINI 1Tim Wyant, PhD, James Lewis, MD, FACG, Walter Reinisch, MD,PhD, Themistocles Dassopoulos, MD, Philip Ginsburg, MD, FACG,Bruce Sands, MD, FACG, Brian Feagan, MD, FACG, Silvio Danese,MD, PhD, Arne Roseth, MD, PhD, Maria Rosario, PhD, HuyuanYang, PhD, Asit Parikh, MD, PhD, Brian Bressler, MD, MS, FRCPC,Takeda Pharmaceuticals International Co., Cambridge, MA, PerelmanSchool of Medicine at the University of Pennsylvania, Philadelphia,PA, Department of Internal Medicine III, Medical University of Vienna,Vienna, Austria, Gastroenterology Division, Washington UniversitySchool of Medicine, St. Louis, MO, Gastroenterology Center ofConnecticut, Hamden, CT, Icahn School of Medicine at Mount Sinai,New York, NY, Robarts Research Institute, University of WesternOntario, London, ON, Canada, Istituto Clinico Humanitas, Milan, Italy,Lovisenberg Diaconal Hospital, Oslo, Norway, Takeda PharmaceuticalsInternational, Inc., Deerfield, IL, Division of Gastroenterology, Universityof British Columbia, Vancouver, BC, CanadaP443. Clinical Benefit of Adalimumab Dose Adjustment for Patients WithModerately to Severely Active Crohn’s Disease in EXTENDJean-Frederic Colombel, MD, Paul Rutgeerts, MD, William Sandborn,MD, Douglas Wolf, MD, Walter Reinisch, MD, Gert Van Assche, MD,Samantha Eichner, MD, Qian Zhou, PhD, Joel Petersson, MD, AnneRobinson, MD, Roopal Thakkar, MD, Icahn School of Medicine atMount Sinai, New York, NY, University of Leuven, Leuven, Belgium,University of California San Diego, La Jolla, CA, Atlanta GastroenterologyAssociates, Atlanta, GA, McMaster University, Hamilton, ON, Canada,AbbVie Inc, North Chicago, ILP444. Improvement of C-Reactive Protein in Certolizumab PegolResponders but Not in Non-Responders in Crohn’s DiseaseDouglas Wolf, MD, FACG, Christine Wolf, MD, Atlanta GastroenterologyAssociates, Atlanta, GAP445. Evaluation of an Interim Crohn’s Disease Outcome Measure(PRO−2) Based on 2 Patient-Reported Components (Stool Frequency,Abdominal Pain) of the Crohn’s Disease Activity Index (CDAI) in theUstekinumab CERTIFI StudyChristopher Gasink, MD, Joshua Friedman, PhD, Long long Gao,PhD, Daphne Chan, PhD, William Sandborn, MD, Brian Feagan, MD,Janssen R&D, LLC, Spring House, PA, University of California SanDiego, La Jolla, CA, Robarts Research Institute, London, ON, CanadaP446. Etrolizumab Population Pharmacokinetics (Pop PK) and CovariateAnalysis in Patients With Moderately to Severely Active Ulcerative Colitis(UC)Xiaohui (Tracey) Wei, PhD, Diana Luca, PhD, Yehong Wang, PhD,Sharon O’Byrne, MD, Rich Erickson, PhD, John Davis, PhD, MeinaTang, PhD, Genentech, Inc., South San Francisco, CAP447. Pregnancy Outcomes After Exposure to Certolizumab Pegol:Results From Safety SurveillanceUma Mahadevan, MD, Séverine Vermeire, MD, Douglas Wolf, MD,Frauke Förger, MD, John Cush, MD, Amanda Golembesky, PhD,Laura Shaughnessy, PhD, Dirk De Cuyper, PhD, Kristel Luijtens, PhD,Sarah Abbas, MD, Megan Clowse, MD, UCSF Medical Center, SanFrancisco, CA, University Hospitals Leuven, Leuven, Belgium, AtlantaGastroenterology Associates, Atlanta, GA, University of Bern, Bern,Switzerland, Baylor Research Institute and Baylor University MedicalCenter, Dallas, TX, UCB Pharma, Raleigh, NC, Duke University MedicalCenter, Durham, NCP448. Comparative Efficacy of Pharmacological Interventions for Post-Operative Prophylaxis After Surgical Resection in Crohn’s Disease: ASystematic Review and Network Meta-analysisSiddharth Singh, MD, Sushil Kumar Garg, MBBS, Darrell Pardi, MD,MS, FACG, Zhen Wang, PhD, Mohammad Murad, MD, MPH, EdwardLoftus, MD, FACG, Gastroenterology and Hepatology, Mayo Clinic,Rochester, MN, University of Minnesota, Minneapolis, MNP449. Idiopathic Inflammatory Demyelinating Disease of the CentralNervous System in Patients With Inflammatory Bowel DiseaseKara De Felice, MD, Martina Novotna, MD, William Faubion, MD,William Tremaine, MD, Orhun Kantarci, MD, Laura Raffals, MD, MayoClinic Gastroenterology and Hepatology, Rochester, MN, Mayo ClinicNeurology, Rochester, MNP450. The Usefulness of Capsule Enteroscopy and Patency in theManagement of Patients With Crohn’s DiseaseJoão Santos-Antunes, MD, Helder Cardoso, MD, Margarida Marques,MD, Amadeu CR Nunes, MD, Susana Lopes, MD, Guilherme Macedo,MD, PhD, Centro Hospitalar S. João, Porto, PortugalP451. Early Life Environment and Natural History of Inflammatory BowelDiseasesAbra Guo, BS, Robin Wilson, BS, Betsy Stevens, BS, Caitlin Russell,BS, MS, Melissa Cohen, BS, Holly Sturgeon, BS, MPH, CosmasGiallourakis, MD, Hamed Khalili, MD, MPH, Deanna Nguyen,MD, Jenny Sauk, MD, Ramnik Xavier, MD, PhD, Vijay Yajnik, MD,PhD, Ashwin Ananthakrishnan, MD, MPH, Gastrointestinal Unit,Massachusetts General Hospital, Boston, MAP452. Endoscopic Skipping of the Distal Terminal IIeum in PediatricCrohn’s DiseaseIshrat Mansuri, MBBS, Joel Fletcher, MD, Parakkal Deepak, MBBS,David Bruining, MD, Amy Kolbe, MD, Jeff Fidler, MD, Sunil Samuel,MBBS, PhD, Edward Loftus, MD, FACG, John Barlow, MD, StephanieHansel, MD, Brenda Becker, BSc, Jeanne Tung, MD, FACG, Divisionof Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester,MN, Division of Gastroenterology and Hepatology, Mayo Clinic,Rochester, MN, Department of Radiology, Mayo Clinic, Rochester,MN, Nottingham University Hospitals NHS Trust, Nottingham, UnitedKingdomP453. The Novel PillCam Crohn’s Disease Capsule Demonstrates SimilarDiagnostic Yield as Ileocolonoscopy in Patients With Active Crohn’sDisease: A Prospective Multicenter International Cohort StudyJonathan Leighton, MD, Debra Helper, MD, Pramod Malik, MD, RussellHavranek, MD, Kim Isaacs, MD, Iris Dotan, MD, Adi Lahat, MD, JohnHorlander, MD, Andrew Tinsley, MD, Ignacio Fernandez-Urien Sainz,MD, Bruno Rosa, MD, Gerrard Mullin, MD, Ian Gralnek, MD, MayoClinic, Scottsdale, AZ, Medicine, Indiana University School of Medicine,Indianapolis, IN, Gastroenterology Associates of Tidewater, Chesapeake,VA, Gastroenterology Clinic of San Antonio, San Antonio, TX, Universityof North Carolina, Chapel Hill, NC, Tel Aviv Sourasky Medical Center(Ichilov), Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel,Louisville Gastroenterology Associates, Louisville, KY, Penn StateHershey Medical Center, Hershey, PA, Hospital de Navarra, Pamplona,Spain, CentroHospitalar do Alto Ave, Guimaraes, Portugal, JohnsHopkins Medical Center, Baltimore, MD, Rambam Medical Center,Haifa, IsraelFor more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.58
Poster Presentations – Sunday, October 19, 3:30 pm - 7:00 pmP454. Outcomes of Fecal Microbiota Transplantation for C. difficileInfection in Patients With Inflammatory Bowel Disease2014 ACG Presidential Poster AwardMonika Fischer, MD, MS, Colleen Kelly, MD, Dina Kao, MD, AishwaryaKuchipudi, MD, Syed-Mohammed Jafri, MD, Mark Blumenkehl, MD,Douglas Rex, MD, Mark Mellow, MD, Nirmal Kaur, MD, Harry Sokol,MD, PhD, Gwen Cook, MS, Emmalee Phelps, BA, Brian Sipe, MD,Medicine/Gastroenterology, IUPUI, Indianapolis, IN, Alpert School ofMedicine of Brown University, Providence, RI, University of Alberta,Edmonton, AB, Canada, Henry Ford Hospital, Detroit, MI, IntegrisDigestive Health Center, Oklahoma City, OK, Hospital Saint-Antoine,Paris, France, St. John’s Hospital, Anderson, INP455. Anal Intraepithelial Neoplasia: Another Cancer to Screen andVaccinate for in Crohn’s DiseaseMubarak Sayyar, MD, Tarek Sawas, MD, Mitesh Patel, MD, FACG,Washington Hospital Center, Washington, DCP456. Quantifying Fecal Tumor Necrosis Factor-α (TNF-α) in Active IBDCompared to Other Forms of Enterocolitis: A Prospective StudyMelvin Bullock, MD, Ravi Kottoor, MD, Candace Aureleus, MD,University of Florida, Jacksonville, Jacksonville, FLP457. Non-Adherence to Topical Mesalamine in Patients With UlcerativeColitisAmanda Ting, BSc, Adam Cheifetz, MD, FACG, Alan Moss, MD, FACG,Gastroenterology, BIDMC, Boston, MAP458. Physicians’ Perspective Regarding Adherence to SystemicTherapies for IBD and Other Immune-Mediated Inflammatory DiseasesAla Sharara, MD, FACG, Alfred Alfred Ammoury, MD, Jad Okais, MD,Raymond Sayegh, MD, American University of Beirut, Beirut, Lebanon,USJ, Beirut, Lebanon, Balamand University, Beirut, Lebanon, LebaneseUniversity, Beirut, LebanonP459. Segmental Sigmoid Polyposis as a Colonoscopic Indicator ofan Ileo-Sigmoid Fistula (ISF) in Crohn’s Disease: A Newly RecognizedPrognostic EntityRaja Taunk, MD, Vivek Kesar, MBBS, Burton Korelitz, MD, MACG,FACG, Lenox Hill Hospital, New York City, NYP460. SP-333, a Guanylate Cyclase C Agonist, Is Safe and Well-Tolerated, Locally Acting Drug Candidate for Treatment of GastrointestinalDisorders and DiseasesLaura Barrow, PharmD, John Foss, PhD, Stephen Comiskey, PhD,Rong Feng, PhD, Gary Jacob, PhD, Kunwar Shailubhai, PhD, MBA,R&D, Synergy Pharmaceuticals, Inc, Doylestown, PAP461. Food Avoidance and Use of Dietary Supplements Among PatientsWith Inflammatory Bowel DiseaseTien-Chun Chen, MD, Guillermina Cruz, MD, Joseph Sellin, MD, JasonHou, MD, Baylor College of Medicine, Houston, TX, Baylor Collegeof Medicine; Michael E. DeBakey Veterans Affairs Medical Center,Houston, TX, Baylor College of Medicine; Center for Innovations inQuality, Effectiveness and Safety (IQuESt); Michael E. DeBakey VeteransAffairs Medical Center, Houston, TXP462. Risk Factors for Campylobacter jejuni Infection and Impact on theDisease Course in Patients With Ulcerative ColitisZubin Arora, MD, Xianrui Wu, MD, Saurabh Mukewar, MD, Bo Shen,MD, FACG, Cleveland Clinic Foundation, Cleveland, OHP463. Role of Colonic Expression of Wnt Inhibitory Factor-1 in UlcerativeColitisJayakrishna Chintanaboina, MD, MPH, Brittany Lippert, BS, DeepPatel, BS, Amanda Tracy, BS, Price Kimberly, BS, Alexander Lalos, MD,Bharat Patel, MD, Edward Sherwin, MD, Christopher Barbarevech, MD,David Rutta, MD, Matthew Haner, PhD, Linda Gutierrez, MD, Medicine,Penn State Hershey Medical Center, Hummelstown, PA, WilkesUniversity, Wilkes-Barre, PA, GI Consultants of Northeast Pennsylvania,Scranton, PA, Mansfield University, Mansfield, PAP464. Endoscopic Balloon Dilation in Crohn’s Disease: The RealImpact on Clinical Disease BehaviorSusana Lopes, MD, Patrícia Andrade, MD, Eduardo Rodrigues-Pinto,MD, Filipe Vilas-Boas, MD, Fernando Magro, MD, PhD, GuilhermeMacedo, MD, PhD, FACG, Gastroenterology, Centro Hospitalar SãoJoão, Porto, PortugalP465. Endoscopic Recurrence After Ileocolectomy in Crohn’s DiseaseSusana Lopes, MD, Patrícia Andrade, MD, Eduardo Rodrigues-Pinto,MD, Filipe Vilas-Boas, MD, Fernando Magro, MD, PhD, GuilhermeMacedo, MD, PhD, FACG, Gastroenterology, Centro Hospitalar SãoJoão, Porto, PortugalP466. POSTER WITHDRAWNP467. Budesonide Foam for Ulcerative Proctitis (UP) and UlcerativeProctosigmoiditis (UPS): Subgroup Analyses of 2 Randomized, Placebo-Controlled, Phase 3 StudiesBrian Bosworth, MD, FACG, William Sandborn, MD, FACG, DavidRubin, MD, FACG, Jing Yu, PhD, Andrew Barrett, PhD, Enoch Bortey,PhD, William Forbes, PharmD, New York-Presbyterian Hospital/WeillCornell MedicalCollege, New York, NY, University of California SanDiego, La Jolla, CA, University of Chicago Medicine, Chicago, IL, SalixPharmaceuticals, Inc., Raleigh, NCP468. Diet Compliance and Its Measurement in a Clinical Trial of Crohn’sDiseaseGayatri Sanku, BS, Prachi Chakradeo, MS, Susan Mikolaitis, MS, RDN,Ali Keshavarzian, MD, FACG, Shahriar Sedghi, MD, Louis Fogg, PhD,Ece Mutlu, MD, MBA, MS, FACG, Rush University Medical Center,Chicago, IL, Mercer University, Macon, GAP469. Prebiotic Compliance and Its Measurement in a Clinical Trial ofCrohn’s DiseaseGayatri Sanku, BS, Prachi Chakradeo, MS, Susan Mikolaitis, MS, RDN,Ali Keshavarzian, MD, FACG, Shahriar Sedghi, MD, Louis Fogg, PhD,Ece Mutlu, MD, MBA, MS, FACG, Rush University Medical Center,Chicago, IL, Mercer University, Macon, GAP470. Efficacy and Tolerability of Budesonide Foam With or WithoutBaseline 5-Aminosalicylic Acid Use in Patients With Ulcerative Proctitis(UP) or Ulcerative Proctosigmoiditis (UPS): Results of 2 Randomized,Placebo-Controlled, Phase 3 StudiesWilliam Sandborn, MD, FACG, Brian Bosworth, MD, FACG, DavidRubin, MD, FACG, Jing Yu, PhD, Andrew Barrett, PhD, Craig Paterson,MD, William Forbes, PharmD, University of California San Diego, LaJolla, CA, New York-Presbyterian Hospital/Weill Cornell Medical College,New York, NY, University of Chicago Medicine, Chicago, IL, SalixPharmaceuticals, Inc., Raleigh, NCP471. Characterization of Mucosal Healing With Adalimumab Treatmentin Patients With Moderately to Severely Active Crohn’s Disease FromEXTENDWalter Reinisch, MD, Jean-Frederic Colombel, MD, Geert D’Haens,MD, William Sandborn, MD, Paul Rutgeerts, MD, Joel Petersson, MD,Samantha Eichner, MD, Qian Zhou, PhD, Annalisa Iezzi, MD, RoopalThakkar, MD, McMaster University, Hamilton, ON, Canada, IcahnSchool of Medicine at Mount Sinai, New York, NY, Academic MedicalCenter, Amsterdam, Netherlands, University of California San Diego,La Jolla, CA, University of Leuven, Leuven, Belgium, AbbVie Inc, NorthChicago, ILP472. Different Methodologies for Determining Mayo Score in ClinicalStudies Can Influence Disease Activity Assessments in Ulcerative ColitisSubrata Ghosh, MD, William Sandborn, MD, Julian Panés, MD, GeertD’Haens, MD, Nattanan Reilly, MD, Andreas Lazar, MD, Bidan Huang,PhD, Anne Robinson, MD, Roopal Thakkar, MD, University of Calgary,Calgary, AB, Canada, University of California San Diego, La Jolla, CA,Hospital Clinic University of Barcelona, Barcelona, Spain, AcademicMedical Center, Amsterdam, Netherlands, AbbVie Inc, North Chicago,IL, AbbVie Deutschland GmbH and Co, KG, Ludwigshafen, GermanyPOSTERSSUNDAY59For more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.
- Page 6 and 7:
Featured LecturesDavid Sun LectureT
- Page 8:
Special EventsThere are numerous op
- Page 12 and 13: ACG's 2014 Optional Friday Coursesa
- Page 15 and 16: asge-sponsored endoscopy courseACG'
- Page 18: Optional Friday Courses / ACG's 201
- Page 21 and 22: ACG's 2014 Postgraduate Course - Sa
- Page 23 and 24: ACG's 2014 Postgraduate Course - Su
- Page 25 and 26: ACG's 2014 Annual Scientific Meetin
- Page 27 and 28: Annual Scientific Meeting Agenda -
- Page 29 and 30: Annual Scientific Meeting Agenda -
- Page 31 and 32: Annual Scientific Meeting Agenda -
- Page 33 and 34: Annual Scientific Meeting Agenda -
- Page 35 and 36: Annual Scientific Meeting Agenda -
- Page 37 and 38: Annual Scientific Meeting Agenda -
- Page 39 and 40: Annual Scientific Meeting - Faculty
- Page 41 and 42: Poster PresentationsSunday, October
- Page 43 and 44: Poster Presentations - Sunday, Octo
- Page 45 and 46: Poster Presentations - Sunday, Octo
- Page 47 and 48: Poster Presentations - Sunday, Octo
- Page 49 and 50: Poster Presentations - Sunday, Octo
- Page 51 and 52: Poster Presentations - Sunday, Octo
- Page 53 and 54: Poster Presentations - Sunday, Octo
- Page 55 and 56: Poster Presentations - Sunday, Octo
- Page 57 and 58: Poster Presentations - Sunday, Octo
- Page 59: Poster Presentations - Sunday, Octo
- Page 63 and 64: Poster Presentations - Sunday, Octo
- Page 65 and 66: Poster Presentations - Sunday, Octo
- Page 67 and 68: Poster Presentations - Sunday, Octo
- Page 69 and 70: Poster Presentations - Monday, Octo
- Page 71 and 72: Poster Presentations - Monday, Octo
- Page 73 and 74: Poster Presentations - Monday, Octo
- Page 75 and 76: Poster Presentations - Monday, Octo
- Page 77 and 78: Poster Presentations - Monday, Octo
- Page 79 and 80: Poster Presentations - Monday, Octo
- Page 81 and 82: Poster Presentations - Monday, Octo
- Page 83 and 84: Poster Presentations - Monday, Octo
- Page 85 and 86: Poster Presentations - Monday, Octo
- Page 87 and 88: Poster Presentations - Monday, Octo
- Page 89 and 90: Poster Presentations - Monday, Octo
- Page 91 and 92: Poster Presentations - Monday, Octo
- Page 93 and 94: Poster Presentations - Monday, Octo
- Page 95 and 96: Poster Presentations - Tuesday, Oct
- Page 97 and 98: Poster Presentations - Tuesday, Oct
- Page 99 and 100: Poster Presentations - Tuesday, Oct
- Page 101 and 102: Poster Presentations - Tuesday, Oct
- Page 103 and 104: Poster Presentations - Tuesday, Oct
- Page 105 and 106: Poster Presentations - Tuesday, Oct
- Page 107 and 108: Poster Presentations - Tuesday, Oct
- Page 109 and 110: Poster Presentations - Tuesday, Oct
- Page 111 and 112:
Poster Presentations - Tuesday, Oct
- Page 113 and 114:
Poster Presentations - Tuesday, Oct
- Page 115 and 116:
Poster Presentations - Tuesday, Oct
- Page 117 and 118:
Poster Presentations - Tuesday, Oct
- Page 119 and 120:
Poster Presentations - Tuesday, Oct
- Page 121 and 122:
Poster Presentations - Tuesday, Oct
- Page 123 and 124:
General InformationAccreditationThe
- Page 125 and 126:
ACG Auxiliary Events and ToursAuxil
- Page 127 and 128:
ACG 2014 Registration FormMail to:
- Page 129 and 130:
Exhibit HallThe science and technol
- Page 131 and 132:
Child Care Registration FormThe Ame
- Page 133:
For ACG 2014 Annual Postgraduate Co